TSC2 clinical trials at UCSF
1 research study open to eligible people
TSC2 is a clinical trial at UCSF. It's for adults and teens with certain types of cancer. The trial is testing a drug called nab-sirolimus to see if it helps treat these cancers.
Showing trials for
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
open to eligible people ages 12 years and up
A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes
San Francisco, California and other locations
Our lead scientists for TSC2 research studies include Brian Schulte, MD.
Last updated: